ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ABL-specific tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), have significantly improved CML treatment, and prevent transformation to the deadly blast phase of the disease [2, 3].